share_log

Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa

Benzinga ·  Dec 21, 2023 06:31
Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment